[to top of second column]
But the group's senior vice president, Ken Johnson, added that FDA must "ensure that the competitive development process remains intact to serve patients and the public."
The medical device industry's lobbying group AdvaMed took a more critical stance, suggesting some of FDA's proposals could needlessly disclose proprietary company information.
"Weakening intellectual property protections is a dangerous recipe for stifling investment in breakthrough products and could significantly impede medical progress and ultimately impede public health," the group said in a statement.
Other recommendations from the FDA task force include:
Publishing inspection reports of drug and food manufacturing plants online.
Publicizing criminal cases against companies regulated by the FDA.
Putting more documents online to relieve a massive backlog of document requests.
One of the agency's toughest critics questioned that last strategy, pointing out that the FDA would actually need more time and money to redact thousands of documents to be posted online.
"There are some important steps forward here, but you can talk about transparency from here to eternity and if you don't have an actual mechanism to make that data available it becomes less meaningful," said Dr. Sidney Wolfe, of the consumer advocacy group Public Citizen.
The FDA's task force will take comments on the recommendations for 60 days and then submit a final list of changes for implementation.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor